‘Adverse event’ won’t delay Serum vaccine plan: Centre | Latest News India - Hindustan Times
close_game
close_game

‘Adverse event’ won’t delay Serum vaccine plan: Centre

Hindustan Times, New Delhi | By
Dec 02, 2020 06:37 AM IST

The remarks were made by Union health secretary Rajesh Bhushan and Indian Council of Medical Research head Dr Balram Bhargava at a weekly government briefing on Covid-19.

Initial assessments after a volunteer’s illness suggested the trial of the Oxford-AstraZeneca vaccine did not need to be halted and the incident will not affect the time lines for the emergency approval process in the country, top officials said on Tuesday — the first reaction from the government on a controversy that had appeared to dampen hopes for an early coronavirus inoculation.

Union Health Secretary Rajesh Bhushan.(Vipin Kumar/HT PHOTO)
Union Health Secretary Rajesh Bhushan.(Vipin Kumar/HT PHOTO)

The remarks were made by Union health secretary Rajesh Bhushan and Indian Council of Medical Research head Dr Balram Bhargava at a weekly government briefing on Covid-19.

Hindustan Times - your fastest source for breaking news! Read now.

The officials also indicated that the country may not need to vaccinate all of India’s population to contain the spread of the disease. “I just want to make this clear that the government has never spoken about vaccinating the entire country. It’s important that we discuss such scientific issues, based on factual information only,” secretary Bhushan said while responding to a question on when a vaccine can be provided to everyone in the country.

Explaining the remark, Bhargava, the ICMR director general, said vaccinating the entire population may not be required if “critical mass of people” is vaccinated and the chain of virus transmission is broken.

Earlier in the briefing, both the officials addressed the controversy triggered by allegations by a Chennai-based man that the clinical trials – sponsored by Serum Institute of India, which is manufacturing the Oxford-AstraZeneca vaccine – left him with serious neurological symptoms.

The Oxford-AstraZeneca vaccine candidate is largely believed to be the first that could be cleared for use among people, with an emergency approval expected in the next couple of months. India is targeting shots for 250-300 million health care workers and essential services staff in its first phase of vaccinations, which it targets to be over by June, 2021.

“This event will not affect timelines in any manner whatsoever. But since there is now a court case, so we will not comment on specifics relating to the case,” Bhushan said, before enumerating five safeguards that are a part of clinical trials in India.

These, according to him, include monitoring by two independent groups of experts, a process of informed consent and detailed vetting of data and review of such incidents by India’s regulators.

“The drugs controller has the authority to not allow vaccine trial to proceed to the next level if the data produces a doubt regarding the vaccine candidate. Currently, Serum Institute’s Covid-19 vaccine candidate has entered the phase 3 stage of the clubbed phase 2/3 trials after receiving necessary approvals post review of all relevant documents. Similarly, Bharat Biotech’s vaccine candidate has also entered the phase 3 clinical trial stage after review of all data they submitted,” said Bhushan.

The volunteer who took ill has sued SII for 5 crore in damages, drawing a legal notice by the Pune-based vaccine maker seeking 100 crore. SII issued a new statement on Tuesday, reiterating the vaccine was safe and produced an immune response and said that its notice was meant to protect the company against attempts to malign it.

Adverse effects, as they are referred to technically, are when trial volunteers develop any serious illness following an inoculation and during the period for which they need to be monitored – usually, this is two months. In this case, the side effects experienced by the volunteer has been said to not have been connected to the vaccine – although the detailed data is being studied.

“All serious adverse events do not need to be informed to every participant. Let us be very clear that many serious adverse events are coincidental. In fact, that is more often the case than causally related serious adverse events, for which, of course, information must be shared,” said Dr Gagandeep Kang, one of the prominent researchers in the field of vaccines in India.

“A trial that we did for illustration, we had 1,462 serious adverse events of which three were considered possibly related (and none of the three were hospitalized), with similar serious adverse events rate in intervention and placebo recipients.”

Unveiling Elections 2024: The Big Picture', a fresh segment in HT's talk show 'The Interview with Kumkum Chadha', where leaders across the political spectrum discuss the upcoming general elections. Watch now!

Get Current Updates on India News, Election 2024, Arvind Kejriwal News Live, Bihar Board 10th Result 2024 Live along with Latest News and Top Headlines from India and around the world.
SHARE THIS ARTICLE ON
Share this article
  • ABOUT THE AUTHOR
    author-default-90x90

    Rhythma Kaul works as an assistant editor at Hindustan Times. She covers health and related topics, including ministry of health and family welfare, government of India.

SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Thursday, March 28, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On